Journal Article Summary
The article discusses the transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension (PAH) who was not responding adequately to oral combination therapy. This topic is significant because PAH is a serious condition that can lead to heart failure, and finding effective treatment options is crucial for improving patient outcomes. The authors aim to provide insights into how this transition can be safely managed, as there is currently no established protocol for such changes in treatment.
The study involved a 56-year-old woman diagnosed with idiopathic PAH who had been treated with a combination of medications, including selexipag. Despite initial improvements in her condition, her cardiac function remained inadequate, prompting the need to switch to subcutaneous treprostinil. The transition was carefully managed over 19 days, during which selexipag was gradually reduced while treprostinil was increased. The results showed that the patient's hemodynamic parameters improved after the transition, indicating that subcutaneous treprostinil was more effective for her condition than the previous oral therapy.
However, the article acknowledges some limitations, including the fact that it is a single case report, which may not be generalizable to all patients with PAH. Additionally, while the transition was successful, patients may experience side effects from treprostinil, such as pain at the injection site and gastrointestinal issues. It is important for patients and caregivers to discuss any concerns or symptoms with a healthcare professional, especially when considering changes in treatment for PAH, to ensure safety and optimal management of the condition.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Adachi Shiro, Nishiyama Itsumure, Yasuda Kenichiro, Yoshida Masahiro, Nakano Yoshihisa, Kondo Takahisa, Murohara Toyoaki. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy. Journal of Cardiology Cases 2022. DOI: 10.1016/j.jccase.2022.02.003. PMID: 35923524. PMCID: PMC9214813.
Featured Pill Pals Product
Tadalafil 5 MG Tablets --- Generic for Cialis --- Ajanta Pharma
Tadalafil 5 MG Tablets — Generic for Cialis — Ajanta Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
